<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00780026</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00016106</org_study_id>
    <nct_id>NCT00780026</nct_id>
  </id_info>
  <brief_title>Intraoperative Glucose Control in Liver Transplant</brief_title>
  <official_title>Effect Of Intraoperative Strict Glycemic Control During Liver Transplantation On Postoperative Morbidity And Mortality</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the proposed study is to evaluate the effectiveness of intraoperative, strict
      glycemic control to improve survival and infection rates following liver transplantation in a
      randomized, prospective trial.Primary objective: To determine if strict intraoperative blood
      glucose control, when compared to standard intraoperative glycemic control, improves 1-year
      recipient survival and decreases surgical complications, including infections, following
      liver transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 2.1 million patients in the United States acquire infections during medical
      care every year. For example, 9%-30% patients who undergo surgery acquire nosocomial
      infections, which increase mortality and morbidity over that expected normally expected and
      increase the cost of care by several billion dollars. Studies have shown that controlling
      high blood glucose levels dramatically improves the recovery of critically ill patients after
      surgery, most notably decreasing the risk of infection. The advantage of strict glycemic
      control in the critically ill patient is now well accepted, and the Institute for Healthcare
      Improvement and Surviving Sepsis Campaign set glycemic control as part of the post-operative
      sepsis management bundle.

      Few studies have investigated the role of strict glycemic control during surgery itself.
      Liver transplantation is a good model for studying glucose control as hyperglycemia almost
      always occurs and the incidence of infection is higher than with other surgical procedures.
      We performed a retrospective review of 184 consecutive adult liver recipients in which
      intra-operative blood glucose levels were measured and treated with insulin. Recipients with
      strict glycemic control were compared to those with poor control for differences in donor and
      recipient demographics, intra-operative blood glucose concentrations, intra-operative insulin
      administered, immunosuppression, post-operative complications, and mortality. Poor glycemic
      control was associated with a significantly increased rate of infection during the first 30
      days post-operatively (48% vs. 33%, P=0.05) and 1-year mortality was significantly increased
      for those recipients with poor intra-operative glucose control (21.9% vs. 8.8%; P = 0.05).
      These data along with the post-operative studies, suggest that the post-transplant mortality
      rate may potentially be decreased by nearly 50% at 1 year and underscore the need for this to
      be confirmed in a prospective trial.

      The goal of this study is to prospectively evaluate the outcomes of liver transplant
      recipients to either strict glucose control (goal of 80-110 mg/dl) or the current standard of
      care (goal of between 180 and 200 mg/dl). The specific aim of this study is to determine if
      strict intra-operative blood glucose control, improves 1-year recipient survival and
      decreases surgical complications, including infections, following liver transplantation. The
      rates of infection at 30 days after surgery and health at one year post- surgery will be
      compared. The frequency of other common post-operation complications will also be studied.
      The proposed study has the potential to have an impact on the intra-operative management of
      all liver transplant recipients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Infection Rates</measure>
    <time_frame>30 days</time_frame>
    <description>Number of participants who sustained an infection after surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>One Year Survival Post Transplant</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospital Length of Stay</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants Who Required Postoperative Blood Transfusion Within 3 Days in the ICU</measure>
    <time_frame>12 months</time_frame>
    <description>Requirements for blood transfusion counted as a binary variable yes/no per participant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for Hemodialysis</measure>
    <time_frame>12 months post surgery</time_frame>
    <description>Number of people who had renal failure in the year following liver transplant and needing hemodialysis to support it;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Biliary Complications</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants who experienced bile leak or biliary Stricture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Venous Thrombotic Complications</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants who were diagnosed with portal vein thrombosis post surgery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Liver Transplant</condition>
  <arm_group>
    <arm_group_label>Strict Glycemic Control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>strict glycemic control (80 to 110 mg/dl)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>standard of care insulin dosing</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin</intervention_name>
    <description>bolus or infusion 80 to 110 mg/dl</description>
    <arm_group_label>Strict Glycemic Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients â‰¥ 18 years old undergoing liver transplantation

          -  Patients willing and capable of giving written informed consent for study
             participation

        Exclusion Criteria:

          -  Multi-organ transplant recipients

          -  Patients receiving a liver incompatible with A, B or O blood types

          -  HIV infected patients

          -  Recipients of an organ from an HIV+ donor

          -  Patients with severe coexisting disease or presenting with any unstable medical
             condition which could affect the study objectives

          -  Patients with a co-existing alcoholic disease who have not been abstinent for at least
             6 month immediately prior to transplantation and are not expected to be able to remain
             abstinent after transplantation

          -  Patients who are unlikely to comply with the study requirements or unable to give
             informed consent

          -  Use of other investigational drugs at the time of enrollment, or within 30 days or 5
             half-lives of enrollment, whichever is longer or if such therapy is to be instituted
             posttransplantation

          -  Patients transplanted for hepatocellular carcinoma exceeding 3 nodules or with nodule
             diameter larger than 5 cm

          -  History of malignancy of any organ system, treated or untreated, within the past 5
             years whether or not there is evidence of local recurrence or metastases, with the
             exception of localized basal cell carcinoma of the skin

          -  Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a
             female after conception and until the termination of gestation, confirmed by a
             positive human chorionic gonadatropin (hCG) laboratory test (&gt; 5 milli-International
             units (mIU/ml)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shawn Pelletier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitry of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2008</study_first_submitted>
  <study_first_submitted_qc>October 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2008</study_first_posted>
  <results_first_submitted>November 3, 2017</results_first_submitted>
  <results_first_submitted_qc>November 3, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 6, 2017</results_first_posted>
  <last_update_submitted>November 3, 2017</last_update_submitted>
  <last_update_submitted_qc>November 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Shawn J. Pelletier, MD</investigator_full_name>
    <investigator_title>Associate Professor of Surgery</investigator_title>
  </responsible_party>
  <keyword>liver</keyword>
  <keyword>transplant</keyword>
  <keyword>blood sugar</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>14 consented individuals did not meet screening criteria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Strict Glycemic Control</title>
          <description>strict glycemic control (80 to 110 mg/dl)
insulin: bolus or infusion 80 to 110 mg/dl</description>
        </group>
        <group group_id="P2">
          <title>Standard of Care Control</title>
          <description>standard of care insulin dosing</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Strict Glycemic Control</title>
          <description>strict glycemic control (80 to 110 mg/dl)
insulin: bolus or infusion 80 to 110 mg/dl</description>
        </group>
        <group group_id="B2">
          <title>Standard of Care Control</title>
          <description>standard of care insulin dosing</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
            <count group_id="B2" value="44"/>
            <count group_id="B3" value="86"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" lower_limit="46" upper_limit="57"/>
                    <measurement group_id="B2" value="55" lower_limit="49.5" upper_limit="59.5"/>
                    <measurement group_id="B3" value="54" lower_limit="49.0" upper_limit="59.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <description>The BMI is defined as the body mass (in kilograms) divided by the square of the body height (in meters).</description>
          <units>kg/m2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.6" lower_limit="22.7" upper_limit="27.6"/>
                    <measurement group_id="B2" value="26.3" lower_limit="23.1" upper_limit="28.8"/>
                    <measurement group_id="B3" value="25.8" lower_limit="23.1" upper_limit="28.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pre-existing conditions</title>
          <description>Preexisting diagnosis for Coronary Artery Disease (CAD)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Diabetes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Coronary Artery Disease(CAD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Infection Rates</title>
        <description>Number of participants who sustained an infection after surgery</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Strict Glycemic Control</title>
            <description>strict glycemic control (80 to 110 mg/dl)
insulin: bolus or infusion 80 to 110 mg/dl</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care Control</title>
            <description>standard of care insulin dosing</description>
          </group>
        </group_list>
        <measure>
          <title>Infection Rates</title>
          <description>Number of participants who sustained an infection after surgery</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bacterial Infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fungal Infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transplant Incision wound</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Viral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.739</p_value>
            <p_value_desc>P value for Bacterial infection</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.235</p_value>
            <p_value_desc>P-value for fungal infection</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.999</p_value>
            <p_value_desc>P value for transplant incision wound</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.999</p_value>
            <p_value_desc>P value for viral infection</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>One Year Survival Post Transplant</title>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Strict Glycemic Control</title>
            <description>strict glycemic control (80 to 110 mg/dl)
insulin: bolus or infusion 80 to 110 mg/dl</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care Control</title>
            <description>standard of care insulin dosing</description>
          </group>
        </group_list>
        <measure>
          <title>One Year Survival Post Transplant</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.670</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospital Length of Stay</title>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Strict Glycemic Control</title>
            <description>strict glycemic control (80 to 110 mg/dl)
insulin: bolus or infusion 80 to 110 mg/dl</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care Control</title>
            <description>standard of care insulin dosing</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Length of Stay</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.60" spread="14.73"/>
                    <measurement group_id="O2" value="24.25" spread="34.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the p-value for the means is &gt; 0.05 between the groups then they will be deemed equivalent.</non_inferiority_desc>
            <p_value>0.745</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants Who Required Postoperative Blood Transfusion Within 3 Days in the ICU</title>
        <description>Requirements for blood transfusion counted as a binary variable yes/no per participant</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Strict Glycemic Control</title>
            <description>strict glycemic control (80 to 110 mg/dl)
insulin: bolus or infusion 80 to 110 mg/dl</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care Control</title>
            <description>standard of care insulin dosing</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Who Required Postoperative Blood Transfusion Within 3 Days in the ICU</title>
          <description>Requirements for blood transfusion counted as a binary variable yes/no per participant</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Need for Hemodialysis</title>
        <description>Number of people who had renal failure in the year following liver transplant and needing hemodialysis to support it;</description>
        <time_frame>12 months post surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Strict Glycemic Control</title>
            <description>strict glycemic control (80 to 110 mg/dl)
insulin: bolus or infusion 80 to 110 mg/dl</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care Control</title>
            <description>standard of care insulin dosing</description>
          </group>
        </group_list>
        <measure>
          <title>Need for Hemodialysis</title>
          <description>Number of people who had renal failure in the year following liver transplant and needing hemodialysis to support it;</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.361</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Biliary Complications</title>
        <description>Number of participants who experienced bile leak or biliary Stricture</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Strict Glycemic Control</title>
            <description>strict glycemic control (80 to 110 mg/dl)
insulin: bolus or infusion 80 to 110 mg/dl</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care Control</title>
            <description>standard of care insulin dosing</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Biliary Complications</title>
          <description>Number of participants who experienced bile leak or biliary Stricture</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>bile leak</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Biliary Stricture</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.710</p_value>
            <p_value_desc>P value for bile leak</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.361</p_value>
            <p_value_desc>This is the p value for Biliary Stricture</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Venous Thrombotic Complications</title>
        <description>Number of participants who were diagnosed with portal vein thrombosis post surgery</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Strict Glycemic Control</title>
            <description>strict glycemic control (80 to 110 mg/dl)
insulin: bolus or infusion 80 to 110 mg/dl</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care Control</title>
            <description>standard of care insulin dosing</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Venous Thrombotic Complications</title>
          <description>Number of participants who were diagnosed with portal vein thrombosis post surgery</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.999</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Strict Glycemic Control</title>
          <description>strict glycemic control (80 to 110 mg/dl)
insulin: bolus or infusion 80 to 110 mg/dl</description>
        </group>
        <group group_id="E2">
          <title>Standard of Care Control</title>
          <description>standard of care insulin dosing</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Graft Loss</sub_title>
                <description>Liver</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Major Cardiac Event</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile Leak</sub_title>
                <description>Bile Leak</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Biliary Stricture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections</sub_title>
                <description>Combination of bacterial, fungal, transplant incision wound or viral infections</description>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dialysis - renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Re-operation for bleeding</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Re-operation - other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Portal Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Subramanian Sathishkumar</name_or_title>
      <organization>University of Michigan</organization>
      <email>ssatish@med.umich.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

